John Hey

John Hey

Company: Alzheon

Job title: CSO


John A. Hey, Ph.D., joined Alzheon, Inc. as CSO and Head of Operations. Dr. Hey comes to Alzheon with more than 25 years of drug discovery and clinical development experience in both Biotechnology and pharmaceutical drug development. Dr. Hey is the scientific and development leader for Alzheon advancing the clinical candidate ALZ-801, an orally bioavailable agent in development as a new disease modifying therapy for Alzheimer’s disease.

Prior to working with Alzheon, Dr. Hey held senior R&D leadership position in drug development at CoMentis, a Biotechnology company focusing on Alzheimer’s disease drug development. As Senior Vice President of CoMentis, Dr. Hey served as the senior executive leader responsible for the b-secretase inhibitor drug development program for Alzheimer’s disease. In this role, he built a drug discovery and lead optimization facility, and spearheaded the nonclinical and clinical development teams responsible for all aspects of early drug development, including: PK/PD, biochemistry, in vitro and in vivo pharmacology, in vitro and in vivo ADME, bioanalytical, preclinical safety, safety pharmacology, translational medicine, medicinal chemistry and clinical development. This work successfully culminated with advancing the first b-secretase inhibitor (CTS-21166) into clinical proof of activity in humans. He then led the program to a $800M partnership with Astellas Pharma in 2008.

Prior to his tenure at CoMentis, Dr. Hey spent 18 at the Schering-Plough Research Institute leading discovery, preclinical and early clinical development teams in multiple therapeutic areas through phase 2. During this time, he also led the preclinical discovery, lead optimization, clinical development activities, strategic planning for 50+ scientists, ADME specialists, toxicologists, clinical and regulatory teams. Dr. Hey has been directly responsible for discovery and development of over 20 NCEs, including several that have advanced to NDA stage and approval. Dr. Hey’s R&D activities also supported the Phase 3 and Phase 4 programs for Schering-Plough’s respiratory disease franchise portfolio, including Claritin®/Clarinex®, Asmanex® and Nasonex®.

Dr. Hey holds a Ph.D. in Pharmacology from the University of Oklahoma and has authored more than 150 peer reviewed scientific publications.


Discussing ALZ-801 – A Phase 3 Ready Conformational Modifier with Disease Modifying for Alzheimer’s Disease 4:50 pm

Presenting a small molecule modifier of protein misfolding through a novel “enveloping MOA” Discussing how these small molecule modifiers represent a promising new class of agents for neurodegenerative diseaseRead more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.